Renal Excretion of Medicines

About 30% of all prescribed medicines leave the body primarily through the kidneys

That number sat with me when I first came across it during my pharmacology reading. Thirty percent. For something as biologically unglamorous as urine output, renal excretion quietly governs the duration and intensity of a huge slice of the medicines people take every day. And yet it rarely gets the attention it deserves outside of clinical pharmacokinetics courses.

So let's fix that.

This piece is part of our pharmacokinetics foundations series. No dosing advice here , just the underlying science of how drugs exit the body via the renal route, why it matters for understanding medicine behaviour, and a few points that I think are genuinely under-explained in most lay resources.

The kidney's three-step filtration process

The kidney does not simply "flush out" drugs the way you might rinse a jar. There are three distinct mechanisms at play, each contributing differently depending on the drug's chemistry.

Glomerular filtration is the first. Blood arrives at the glomerulus , a dense knot of capillaries sitting inside the Bowman's capsule , under enough pressure to push water, small molecules, and dissolved substances through into the tubular fluid. Drugs that are small, water-soluble, and not bound to plasma proteins pass through freely. That last part matters: a drug heavily bound to albumin or other plasma proteins cannot be filtered at the glomerulus. Only the free (unbound) fraction crosses. Protein binding is therefore one of the key variables that pharmacologists watch when predicting how fast a compound exits renally.

Tubular secretion is the second mechanism, and it's the one that surprises people. The proximal tubule is lined with active transporter proteins; organic anion transporters (OATs) and organic cation transporters (OCTs) being the main families, that pull drugs out of the peritubular capillaries and dump them directly into the tubular lumen. This is an active, energy-dependent process that can work even when a drug is protein-bound. Some drugs are so efficiently secreted this way that they're nearly completely cleared from the blood in a single pass through the kidney. Drug-drug interactions at these transporter sites are a real clinical consideration; two compounds competing for the same OAT can slow each other's excretion in ways that significantly change their effective half-lives.

Tubular reabsorption runs in the opposite direction. As tubular fluid flows through the nephron, lipid-soluble (lipophilic) molecules can passively diffuse back across the tubular wall and re-enter the bloodstream. The kidney can't easily distinguish between a drug and a nutrient on the basis of lipophilicity alone. Highly lipophilic compounds get reabsorbed extensively, which is one reason they tend to have long half-lives, they keep cycling back. This is also why hepatic metabolism matters so much for lipophilic drugs: converting them to more polar (hydrophilic) metabolites via the liver helps "trap" them in the tubular fluid so they can be excreted rather than reclaimed.

Urinary pH plays a role in reabsorption too. Weak acids and weak bases exist in equilibrium between ionised and un-ionised forms, and it's only the un-ionised form that can diffuse back across the tubular membrane. Acidic urine favours reabsorption of weak acids (they stay un-ionised); alkaline urine does the opposite. This is basic Henderson-Hasselbalch chemistry, and it's the kind of thing that comes up a lot in pharmacokinetics discussions around bioavailability and distribution.

Renal clearance as a number

Pharmacologists quantify this whole process with a value called renal clearance (CL_R), expressed in millilitres per minute. It represents the theoretical volume of plasma completely cleared of a drug by the kidneys per unit time. For reference, the normal glomerular filtration rate in a healthy adult is roughly 120–130 mL/min. If a drug's renal clearance exceeds that, tubular secretion must be contributing; the kidney is clearing more drug than the GFR alone could account for. If clearance is much lower than the GFR, significant tubular reabsorption is happening.

The formula is straightforward: CL_R = (urine flow rate × urine drug concentration) ÷ plasma drug concentration. Simple on paper; a bit fussier to measure in practice because urine collection needs to be complete and timed accurately.

Where peptides sit in this picture

I write a lot about peptides on this site, so it would feel incomplete not to mention how they interact with renal excretion. Short peptides, sequences of just a few amino acids held together by peptide bonds, are small enough to pass through the glomerular filter relatively freely, at least compared to large protein biologics. But they also face enzymatic degradation in the tubular fluid and the proximal tubule brush border, where peptidases cleave them efficiently. So for most short peptides, renal elimination involves both filtration and local enzymatic breakdown rather than excretion of the intact molecule.

Longer or more structurally modified peptides; including classes like GLP-1 receptor agonists, have been specifically engineered to resist this rapid degradation, which extends their half-lives. Understanding renal handling is a core part of how pharmaceutical chemists design these molecules. It's genuinely one of my favourite areas of drug design: the way structural tweaks at the molecular level translate to measurable changes in how long something stays in the body is elegant in a very satisfying way.

I'll admit I got this wrong for years, I used to assume that "small molecule = fast renal excretion", full stop. The tubular reabsorption piece complicated that picture once I actually sat down with the primary literature.

Factors that alter renal excretion in practice

Age is the big one. GFR declines progressively from around the fourth decade of life, and by age 80 it's often less than half the value seen in a healthy 25-year-old. This has significant implications for renally-cleared medicines in older adults; not something this article will prescribe around, but it's an important reason why clinical pharmacokinetics pays so much attention to renal function when assessing dosing regimens.

Kidney disease (in various forms) reduces GFR further and can also disrupt tubular secretion and reabsorption. Pregnancy increases renal blood flow and GFR, sometimes substantially, which can affect the clearance of renally-excreted compounds in the opposite direction. Hydration status matters too, concentrated urine increases the chance of reabsorption simply by increasing drug concentration in the tubular fluid relative to plasma.

Certain drugs are known to inhibit or induce the OAT and OCT transporters responsible for tubular secretion, creating meaningful interaction potential. The Therapeutic Goods Administration's guidance on pharmacokinetic drug interactions references transporter-based effects as part of its assessment criteria for new medicines, and those interactions can be clinically significant in ways that aren't always predictable from looking at chemistry alone.

Renal excretion and cannabinoids; a brief note

For anyone following our cannabinoid content: most cannabinoids, including cannabidiol and tetrahydrocannabinol, are highly lipophilic. They are not primarily renally excreted as parent compounds. Instead, they undergo extensive hepatic metabolism (including significant first-pass metabolism after oral dosing), and it's their more polar metabolites that appear in urine. THC-COOH, the carboxylated metabolite of THC, is the compound targeted in standard urine drug screens, not THC itself. The renal route matters here mostly at the metabolite level rather than for the parent cannabinoid molecule.

This is worth knowing not just for pharmacology reasons but because it shapes how long cannabinoid metabolites remain detectable after use, a question that comes up frequently in workplace and forensic contexts.

One thing the textbooks understate

Honestly, I think most pharmacology writing undersells how dynamic renal excretion is. It's presented as a clearance mechanism, passive, inevitable, a drain at the bottom of the bathtub. But the transporter systems, the pH-dependent equilibria, the competition effects between co-administered drugs, the physiological variation across age and health status; all of it means renal excretion is better understood as an active process with multiple points of regulation. That framing changes how you think about why two people given the same medicine can have measurably different plasma concentrations twelve hours later.

Between long runs along the Cooks River and working through a particularly good true-crime series, I keep coming back to the kidney as one of pharmacology's most underrated characters. It does a lot of the work quietly, and it does it in three different ways at once.

Sources

• Drug Metabolism and Pharmacokinetics, StatPearls, NCBI Bookshelf
• Australian Regulatory Guidelines for Prescription Medicines, Therapeutic Goods Administration
• Renal Drug Transporters and Drug Interactions; Clinical Journal of the American Society of Nephrology, NCBI
• Poisons Standard (current), Australian Government Department of Health and Aged Care

, Priya Nandakumar, Pharmacology writer, peptides & PK